The recent passage of the Biosecure Act in the US House of Representatives could impact the global biotech landscape, particularly for Chinese companies, Pulse News reported Thursday.
The bill seeks to lower the influence of Chinese biotech companies such as Wuxi Biologics (HKG:2269), Wuxi AppTec (HKG:2359, SHA:603259), and BGI Genomics (SHE:300676).
This move could open up new business opportunities for South Korean biotech companies such as Samsung Biologics (KRX:207940) and ST Pharm (KOSDAQ:A237690), the Korean news outlet said.
Samsung Biologics has already witnessed higher demand while ST Pharm was recently chosen as a supplier for a drug that was previously sourced from China, according to the report.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price (HKD): $976000.00, Change: $-5000, Percent Change: -0.51%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.